4Sc AG develops drugs against cancer. See these slides from February 2022. Their prime candidate drug is Resminostat, a small molecule that can be administered orally. It already has orphan status for use against mycosis fungoides and sezary syndrome, which are both
4Sc AG: promising biotech net-net, also falling knife and 5-year low
4Sc AG: promising biotech net-net, also…
4Sc AG: promising biotech net-net, also falling knife and 5-year low
4Sc AG develops drugs against cancer. See these slides from February 2022. Their prime candidate drug is Resminostat, a small molecule that can be administered orally. It already has orphan status for use against mycosis fungoides and sezary syndrome, which are both